Chapwood Capital Investment Management LLC Takes $275,000 Position in Amgen, Inc. (NASDAQ:AMGN)
Chapwood Capital Investment Management LLC bought a new stake in shares of Amgen, Inc. (NASDAQ:AMGN) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 1,140 shares of the medical research company’s stock, valued at approximately $275,000.
Several other hedge funds and other institutional investors also recently added to or reduced their stakes in AMGN. Nuveen Asset Management LLC boosted its holdings in Amgen by 1,334.9% during the 2nd quarter. Nuveen Asset Management LLC now owns 4,942,807 shares of the medical research company’s stock valued at $910,860,000 after acquiring an additional 4,598,329 shares during the period. BlackRock Inc. boosted its holdings in Amgen by 3.4% during the 2nd quarter. BlackRock Inc. now owns 47,717,316 shares of the medical research company’s stock valued at $8,793,346,000 after acquiring an additional 1,585,911 shares during the period. Johanson Financial Advisors Inc. boosted its holdings in Amgen by 24,240.9% during the 4th quarter. Johanson Financial Advisors Inc. now owns 1,216,801 shares of the medical research company’s stock valued at $5,052,000 after acquiring an additional 1,211,802 shares during the period. Railway Pension Investments Ltd boosted its holdings in Amgen by 158.2% during the 3rd quarter. Railway Pension Investments Ltd now owns 651,796 shares of the medical research company’s stock valued at $126,129,000 after acquiring an additional 399,317 shares during the period. Finally, Beutel Goodman & Co Ltd. boosted its holdings in Amgen by 50.5% during the 2nd quarter. Beutel Goodman & Co Ltd. now owns 1,100,511 shares of the medical research company’s stock valued at $154,859,000 after acquiring an additional 369,142 shares during the period. 76.78% of the stock is currently owned by hedge funds and other institutional investors.
A number of equities analysts recently issued reports on the company. JPMorgan Chase & Co. restated a “hold” rating on shares of Amgen in a report on Sunday. Mizuho restated a “hold” rating and set a $212.00 price objective on shares of Amgen in a report on Sunday, September 29th. Bank of America assumed coverage on Amgen in a report on Wednesday, October 16th. They set a “neutral” rating and a $215.00 price objective for the company. Oppenheimer boosted their price objective on Amgen from to in a report on Tuesday. Finally, Leerink Swann boosted their price objective on Amgen from $189.00 to $205.00 and gave the company a “market perform” rating in a report on Wednesday, October 30th. Ten research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $236.33.
Amgen (NASDAQ:AMGN) last issued its earnings results on Tuesday, October 29th. The medical research company reported $3.66 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $3.53 by $0.13. Amgen had a return on equity of 80.26% and a net margin of 34.48%. The business had revenue of $5.74 billion during the quarter, compared to analysts’ expectations of $5.63 billion. During the same period in the prior year, the business earned $3.69 EPS. The business’s revenue for the quarter was down 2.8% compared to the same quarter last year. Analysts expect that Amgen, Inc. will post 14.66 EPS for the current year.
The business also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, February 14th will be given a $1.60 dividend. This represents a $6.40 annualized dividend and a dividend yield of 2.69%. This is a positive change from Amgen’s previous quarterly dividend of $1.45. The ex-dividend date is Thursday, February 13th. Amgen’s payout ratio is presently 40.28%.
In other news, CFO David W. Meline sold 8,737 shares of the business’s stock in a transaction on Monday, November 25th. The stock was sold at an average price of $234.36, for a total value of $2,047,603.32. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director R Sanders Williams sold 425 shares of the business’s stock in a transaction on Wednesday, November 6th. The stock was sold at an average price of $215.45, for a total value of $91,566.25. Following the completion of the transaction, the director now directly owns 5,413 shares of the company’s stock, valued at $1,166,230.85. The disclosure for this sale can be found here. Over the last three months, insiders sold 18,162 shares of company stock valued at $4,214,030. Corporate insiders own 0.25% of the company’s stock.
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.
Featured Article: Most Active Stocks
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.